The Korean Academy of Asthma Allergy and Clinical Immunology guidelines for sublingual immunotherapy
- Author:
Gwanghui RYU
1
;
Hye Mi JEE
;
Hwa Young LEE
;
Sung-Yoon KANG
;
Kyunghoon KIM
;
Ju Hee KIM
;
Kyung Hee PARK
;
So-Young PARK
;
Myong Soon SUNG
;
Youngsoo LEE
;
Eun-Ae YANG
;
Jin-Young MIN
;
Eun Kyo HA
;
Sang Min LEE
;
Yong Won LEE
;
Eun Hee CHUNG
;
Sun Hee CHOI
;
Young-Il KOH
;
Seon Tae KIM
;
Dong-Ho NAHM
;
Jung Won PARK
;
Jung Yeon SHIM
;
Young Min AN
;
Man Yong HAN
;
Jeong-Hee CHOI
;
Yoo Seob SHIN
;
Doo Hee HAN
;
Author Information
- Publication Type:REVIEW
- From:Allergy, Asthma & Respiratory Disease 2024;12(3):125-133
- CountryRepublic of Korea
- Language:English
- Abstract: Allergen immunotherapy (AIT) has been used for over a century and has been demonstrated to be effective in treating patients with various allergic diseases. AIT allergens can be administered through various routes, including subcutaneous, sublingual, intralymphatic, oral, or epicutaneous routes. Sublingual immunotherapy (SLIT) has recently gained clinical interest, and it is considered an alternative treatment for allergic rhinitis (AR) and asthma. This review provides an overview of the current evidence-based studies that address the use of SLIT for treating AR, including (1) mechanisms of action, (2) appropriate patient selection for SLIT, (3) the current available SLIT products in Korea, and (4) updated information on its efficacy and safety. Finally, this guideline aims to provide the clinician with practical considerations for SLIT.
